Summary

The Intra-Aortic Balloon Pump in Cardiogenic Shock II [IABP-SHOCK II; NCT00491036] trial failed to demonstrate a significant reduction in 30-day mortality with use of an IABP compared with best available medical therapy alone in patients with acute myocardial infarction complicated by cardiogenic shock.